Loading…

IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking

Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2006-03, Vol.116 (3), p.833-841
Main Authors: Strait, Richard T, Morris, Suzanne C, Finkelman, Fred D
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 841
container_issue 3
container_start_page 833
container_title The Journal of clinical investigation
container_volume 116
creator Strait, Richard T
Morris, Suzanne C
Finkelman, Fred D
description Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.
doi_str_mv 10.1172/JCI25575
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1378186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67706011</sourcerecordid><originalsourceid>FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3</originalsourceid><addsrcrecordid>eNqFkU9LxDAQxXNQXF0FP4Hk5K2aNEnTXgRZ_FMRBNFzSdKxjbZJbbKLXv3kVl1FT56Gmff4zRsGoX1KjiiV6fHVokyFkGIDbROS0qSQLJ-hnRAeCaGcC76FZjTjRS4I20ZvZXOR6M6bJ-sarFy02tcWArautdpGXDZnSQ-1VRHqSVdD-9qpF_thwCu78ji2o182LdY-tp-ABtwkRhgNDNF6Nw1rfG5wo_pe4duy1NiMPoSks-5j6y7afFBdgL11naP787O7xWVyfXNRLk6vkyEtRExkwRkROpcMRJEbEJADrYUsai0NkQUBeKhNxgFSU2sGHLI8YxKmJiVCGTZHJ1_cYamniwy4OKquGkbbq_G18spWfxVn26rxq4oymdOJNUeHa8Don5cQYtXbYKDrlAO_DFUmJckIpf8aU8JzToWYjAe_I_1k-f4PewcFwZK0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20484155</pqid></control><display><type>article</type><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</creator><creatorcontrib>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</creatorcontrib><description>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/JCI25575</identifier><identifier>PMID: 16498503</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Anaphylaxis - immunology ; Anaphylaxis - prevention &amp; control ; Animals ; Antibodies, Blocking - physiology ; Antigens - immunology ; Antigens - metabolism ; Cross-Linking Reagents - metabolism ; Immunoglobulin D - metabolism ; Immunoglobulin E - metabolism ; Immunoglobulin E - physiology ; Immunoglobulin G - metabolism ; Immunoglobulin G - pharmacology ; Mast Cells - immunology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Receptors, IgG - metabolism</subject><ispartof>The Journal of clinical investigation, 2006-03, Vol.116 (3), p.833-841</ispartof><rights>Copyright © 2006, American Society for Clinical Investigation 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378186/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378186/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16498503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strait, Richard T</creatorcontrib><creatorcontrib>Morris, Suzanne C</creatorcontrib><creatorcontrib>Finkelman, Fred D</creatorcontrib><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</description><subject>Anaphylaxis - immunology</subject><subject>Anaphylaxis - prevention &amp; control</subject><subject>Animals</subject><subject>Antibodies, Blocking - physiology</subject><subject>Antigens - immunology</subject><subject>Antigens - metabolism</subject><subject>Cross-Linking Reagents - metabolism</subject><subject>Immunoglobulin D - metabolism</subject><subject>Immunoglobulin E - metabolism</subject><subject>Immunoglobulin E - physiology</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunoglobulin G - pharmacology</subject><subject>Mast Cells - immunology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Receptors, IgG - metabolism</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkU9LxDAQxXNQXF0FP4Hk5K2aNEnTXgRZ_FMRBNFzSdKxjbZJbbKLXv3kVl1FT56Gmff4zRsGoX1KjiiV6fHVokyFkGIDbROS0qSQLJ-hnRAeCaGcC76FZjTjRS4I20ZvZXOR6M6bJ-sarFy02tcWArautdpGXDZnSQ-1VRHqSVdD-9qpF_thwCu78ji2o182LdY-tp-ABtwkRhgNDNF6Nw1rfG5wo_pe4duy1NiMPoSks-5j6y7afFBdgL11naP787O7xWVyfXNRLk6vkyEtRExkwRkROpcMRJEbEJADrYUsai0NkQUBeKhNxgFSU2sGHLI8YxKmJiVCGTZHJ1_cYamniwy4OKquGkbbq_G18spWfxVn26rxq4oymdOJNUeHa8Don5cQYtXbYKDrlAO_DFUmJckIpf8aU8JzToWYjAe_I_1k-f4PewcFwZK0</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Strait, Richard T</creator><creator>Morris, Suzanne C</creator><creator>Finkelman, Fred D</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20060301</creationdate><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><author>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anaphylaxis - immunology</topic><topic>Anaphylaxis - prevention &amp; control</topic><topic>Animals</topic><topic>Antibodies, Blocking - physiology</topic><topic>Antigens - immunology</topic><topic>Antigens - metabolism</topic><topic>Cross-Linking Reagents - metabolism</topic><topic>Immunoglobulin D - metabolism</topic><topic>Immunoglobulin E - metabolism</topic><topic>Immunoglobulin E - physiology</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunoglobulin G - pharmacology</topic><topic>Mast Cells - immunology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Receptors, IgG - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strait, Richard T</creatorcontrib><creatorcontrib>Morris, Suzanne C</creatorcontrib><creatorcontrib>Finkelman, Fred D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strait, Richard T</au><au>Morris, Suzanne C</au><au>Finkelman, Fred D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>116</volume><issue>3</issue><spage>833</spage><epage>841</epage><pages>833-841</pages><issn>0021-9738</issn><abstract>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>16498503</pmid><doi>10.1172/JCI25575</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 2006-03, Vol.116 (3), p.833-841
issn 0021-9738
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1378186
source PubMed Central; EZB Electronic Journals Library
subjects Anaphylaxis - immunology
Anaphylaxis - prevention & control
Animals
Antibodies, Blocking - physiology
Antigens - immunology
Antigens - metabolism
Cross-Linking Reagents - metabolism
Immunoglobulin D - metabolism
Immunoglobulin E - metabolism
Immunoglobulin E - physiology
Immunoglobulin G - metabolism
Immunoglobulin G - pharmacology
Mast Cells - immunology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Receptors, IgG - metabolism
title IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IgG-blocking%20antibodies%20inhibit%20IgE-mediated%20anaphylaxis%20in%20vivo%20through%20both%20antigen%20interception%20and%20Fc%20gamma%20RIIb%20cross-linking&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Strait,%20Richard%20T&rft.date=2006-03-01&rft.volume=116&rft.issue=3&rft.spage=833&rft.epage=841&rft.pages=833-841&rft.issn=0021-9738&rft_id=info:doi/10.1172/JCI25575&rft_dat=%3Cproquest_pubme%3E67706011%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20484155&rft_id=info:pmid/16498503&rfr_iscdi=true